The protection covers the company’s PIFA Rapid Assay and the unique methods it uses for detecting platelet factor 4 antibodies.
"This patent is particularly important because it protects the antigen that gives our tests their superior accuracy,” said chairman and co-founder Raymond Akers.
“With published studies that demonstrate that our tests never deliver a false positive result, we believe them to be the most accurate available way to rule out HIT."
The device takes 10 minutes to assess for heparin-induced thrombocytopenia, or HIT, where the blood clots instead of thins.
The process of assessing a patient for HIT requires expensive blood tests that can take several days to turn around.
The diagnostic is the only one of its kind to receive sign off from America’s all-powerful Food & Drug Administration.